MSB 2.17% $1.13 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-486

  1. 1,904 Posts.
    lightbulb Created with Sketch. 491
    Then instead of FDA notifying MSB that Clinical Data Sufficient for Refiling aGVHD BLA they could have said "Do not refile, this is not the data we are looking for".

    I mean you treat users here like they are stupid but the tenacity of you suggesting the FDA would not have the balls to tell MSB where to put their data if it was insufficient is another level of absurd.


 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.